MADRID, 22 September (EUROPA PRESS) –
Merck and Pfizer have announced that the New England Journal of Medicine (NEJM) in its online edition has published the results of the Phase III study ‘JAVELIN Bladder 100’ which describes the efficacy and safety of ‘Bavencio’ (avelumab) for first-line maintenance treatment in various subgroups of patients with locally advanced or metastatic urothelial carcinoma (UC) and patient-reported outcomes (PRO).
In June, the American Drug Agency (FDA) approved avelumab for the maintenance treatment of patients with locally advanced or metastatic UC who have not developed after first-line platinum chemotherapy, based on the results. from ̵
In the study, which was published at the same time as presenting further analyzes at the virtual congress of the European Society of Medical Oncology (ESMO) 2020, avelumab together with the best supportive care (BSC, for its acronym in English), significantly improved median overall survival ( OS) compared with BSC monotherapy in the two primary populations of all randomized patients and patients whose tumors were PD-L1 positive, and significantly more patients receiving avelumab as treatment Frontline maintenance lived after one year.
“These data, which support recent FDA approval and updates to the National Comprehensive Cancer Network (NCCN) and ESMO guidelines, establish that first-line treatment of avelumab may radically change clinical practice for the treatment of patients with locally advanced or metastatic urothelial cancer,” said Genitourinary Oncology. the leader, head of solid tumor research at the Barts Cancer Institute of Queen Mary University of London and head of the Barts Cancer Center of London, Thomas Powles.
Similarly, it has been pointed out that the increase in overall survival with the maintenance regimen avelumab was observed in all subgroups studied, this increase in overall survival was obtained without a detrimental effect on the patients’ quality of life.